US HLA Typing for Transplant Market (2025-2030)
The US HLA Typing for Transplant Market was valued at $485.5 Million in 2025 and projected to reach to $665.2 Million by 2030, representing a compound annual growth rate of 6.5%. The US HLA typing for transplant market is positioned for steady growth driven by rising organ transplant demand, aging population demographics, and healthcare provider investments in advanced diagnostic technologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US HLA Typing for Transplant Market Trends and Insights
- The US market benefits from advanced healthcare infrastructure, high transplant volumes, and increasing adoption of molecular HLA typing technologies that improve graft compatibility and patient outcomes.
- In the US, rising demand for organ transplantation, coupled with regulatory support for precision medicine and immunogenicity assessment, drives market expansion throughout the forecast period. The US HLA typing market is characterized by strong investment in next-generation sequencing (NGS) platforms and enhanced pre-transplant testing protocols.
- The US healthcare system's emphasis on reducing graft rejection rates and improving long-term transplant survival has accelerated the adoption of high-resolution HLA typing methods.
- Between 2025 and 2030, the US market will continue to benefit from technological innovation, increased awareness among transplant centers, and growing reimbursement coverage for advanced HLA testing procedures..
Key Market Statistics
- CAGR (2025-2030) 6.5% CAGR
- Market Size, 2025 ~USD 485.5 Million
- Forecast, 2030 ~USD 665.2 Million
- Country US
US HLA Typing for Transplant Market Overview
Market Size & Growth :
The US HLA typing for transplant market is valued at $485.5 million in 2025 and is projected to reach $665.2 million by 2030, growing at a CAGR of 6.5%, outpacing the global average of 6%.
Advanced Healthcare Infrastructure :
The US benefits from state-of-the-art transplant centers, sophisticated laboratory capabilities, and widespread adoption of molecular HLA typing technologies that enhance graft compatibility and long-term patient outcomes.
High Transplant Volumes :
The US performs over 40,000 organ transplants annually, driving consistent demand for HLA typing services across kidney, heart, liver, and lung transplantation programs nationwide.
Molecular Technology Adoption :
Increasing shift from serological to next-generation sequencing (NGS) and molecular HLA typing methods in US transplant centers improves accuracy, reduces crossmatch failures, and supports precision medicine initiatives.
US HLA Typing for Transplant Market Dynamics
- Molecular HLA typing adoption continues to accelerate as transplant centers prioritize improved graft outcomes and reduced rejection rates.
- Regulatory support, reimbursement coverage expansion, and integration with electronic health records systems further strengthen market momentum.
- The competitive landscape features both established diagnostic companies and emerging molecular testing providers expanding their US market presence through strategic partnerships with major transplant networks and hospital systems..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Key Takeaways
- The US HLA typing for transplant market is valued at $485.5 million in 2025 and will reach $665.2 million by 2030 at a 6.5% CAGR.
- The US market is driven by high organ transplant volumes, advanced healthcare infrastructure, and adoption of molecular HLA typing technologies.
- Next-generation sequencing and high-resolution HLA typing methods are increasingly adopted across US transplant centers to improve graft outcomes.
- The US market benefits from strong reimbursement policies, regulatory support for precision medicine, and growing awareness of immunogenicity assessment.
HLA Typing for Transplant Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | INDEPENDENT REFERENCE LABORATORIES (End User) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6% from 2025 to 2030 |
| Largest Segment | DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 1.05 (2025) |
| Revenue Forecast (Billions) | ~USD 1.4 (2030) |
| Segments Covered | Product & Service, Technology, Type, Application, Transplant Type, End User |
US HLA Typing for Transplant Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Consumables
- Software & Services
By Technology
- Molecular Assays
- Non-Molecular Assays
By Type
- Antibody Screening
- Chimerism Monitoring
- Next-Generation Sequencing
- Other Diagnostic Applications
- Other Pcr-Based Molecular Assays
- Other Sequencing-Based Molecular Assays
- Pcr-Based Molecular Assays
- Real-Time Pcr
- Sanger Sequencing
- Sequence-Specific Oligonucleotide-Pcr
- Sequence-Specific Primer-Pcr
- Sequencing-Based Molecular Assays
By Application
- Diagnostic Applications
- Research Applications
By Transplant Type
- Soft-Tissue Transplants
- Solid Organ Transplants
- Stem Cell Transplants
By End User
- Hospitals & Transplant Centers
- Independent Reference Laboratories
- Research Laboratories & Academic Institutes
Target Audience
- Transplant Diagnostic Companies : In vitro diagnostics and molecular testing providers need US market data to benchmark performance, identify expansion opportunities, and develop targeted sales strategies for transplant centers and reference labs.
- Hospital & Transplant Networks : US transplant programs and hospital systems require market intelligence to evaluate HLA typing technology investments, assess vendor competitiveness, and optimize laboratory service offerings.
- Medical Device & Reagent Manufacturers : Companies developing HLA typing platforms, sequencing reagents, and automation solutions need US-specific demand forecasts and adoption trends to guide R&D priorities and commercialization timelines.
- Healthcare Investors & Consultants : Private equity, venture capital, and management consulting firms require detailed US market analysis to evaluate investment opportunities, assess portfolio company performance, and identify acquisition targets.
- Regulatory & Compliance Professionals : Quality assurance, regulatory affairs, and compliance teams need US-specific market context on FDA requirements, laboratory standards, and reimbursement policies to ensure operational alignment.
Key Companies in the US HLA Typing for Transplant Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Instruments,Reagents,Software, |
| QUIDEL CORPORATION | United States | Public Company | Instruments (Transfusion & Molecular Platforms used in HLA/compatibility workflows),Reagents & Consumables (Antibody Screening, Donor Typing, Molecular Assays),Software & Informatics, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing,Sanger-based HLA typing, |
| ILLUMINA, INC. | United States | Public Company | NGS instruments,NGS reagents and consumables,Software and DRAGEN-based analysis, |
| QIAGEN | Netherlands | Public Company | Reagents & Assays (PCR, NGS, Sanger HLA, immune response),Instruments (PCR, NGS, sample prep, QC),Software & Bioinformatics (HLA typing, chimerism, data analysis), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Instruments (PCR, real-time, supporting platforms),Reagents & consumables for HLA typing and chimerism,Software & informatics for transplant workflows, |
| CAREDX, INC. | United States | Public Company | PCR-based HLA typing (SSO, SSP, Real-time),NGS-based HLA typing (AlloSeq Tx and related),Sanger-based HLA typing, |
| DIASORIN S.P.A. | Italy | Public Company | Reagents and assays (HLA-related and transplant-adjacent),Instruments and platforms (LIAISON, Simplexa, xMAP-based systems),Software and informatics for transplant workflows, |
| BECTON, DICKINSON AND COMPANY | United States | ||
| EUROBIO SCIENTIFIC | France | Public Company | Reagents (PCR, NGS, Sanger),Software (HLA typing, data analysis),Instruments and related hardware, |
KINDRED HEALTHCARE INC.
Kindred Healthcare Inc. is a large private healthcare services company founded in 1985 in the United States, employing 64,200 people. The company operates across multiple healthcare service segments.
QUIDEL CORPORATION
Quidel Corporation is a publicly traded diagnostic company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic testing solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large publicly traded life sciences company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded genomics company founded in 1998 in the United States with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
QIAGEN
QIAGEN is a publicly traded molecular diagnostics company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample and assay technologies for molecular testing.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a publicly traded life sciences company founded in 1952 in the United States with 7,450 employees. The company manufactures and distributes clinical diagnostic products and laboratory reagents.
CAREDX, INC.
CareDx, Inc. is a publicly traded molecular diagnostics company founded in 1998 in the United States with 763 employees. The company specializes in transplant diagnostics and precision medicine solutions.
DIASORIN S.P.A.
DiaSorin S.p.A. is a publicly traded Italian diagnostics company founded in 1968 with 3,242 employees. The company specializes in immunodiagnostic and molecular diagnostic products.
BECTON, DICKINSON AND COMPANY
Insufficient data provided for company description.
EUROBIO SCIENTIFIC
Eurobio Scientific is a publicly traded French diagnostics company founded in 1997 with 343 employees. The company develops and distributes in vitro diagnostic products.
Reasons to Buy this Report
- US-Specific Market Sizing : Obtain precise 2025-2030 market valuations and growth projections exclusive to the United States, enabling accurate budget allocation and revenue forecasting for US transplant diagnostic operations.
- Competitive Landscape Intelligence : Identify leading HLA typing providers, emerging competitors, and market share dynamics specific to US transplant centers, hospitals, and reference laboratories to inform strategic positioning.
- Technology Adoption Trends : Understand the pace of molecular HLA typing adoption across US regions, transplant network preferences, and reimbursement drivers to optimize product development and go-to-market strategies.
- Regulatory & Reimbursement Insights : Access detailed analysis of US FDA regulations, CPT coding, insurance coverage policies, and Medicare/Medicaid reimbursement trends impacting HLA typing service profitability and market access.
- Growth Opportunity Identification : Discover high-growth segments within US transplant programs, underserved regions, and emerging applications to prioritize expansion investments and partnership development initiatives.
Frequently asked questions
What is the current size of the US HLA typing for transplant market?
The US HLA typing for transplant market is valued at $485.5 million in 2025.
What is the projected market size for the US by 2030?
The US HLA typing for transplant market is projected to reach $665.2 million by 2030.
What is the growth rate of the US HLA typing market?
The US HLA typing for transplant market is expected to grow at a compound annual growth rate of 6.5% from 2025 to 2030.
What technologies are driving growth in the US HLA typing market?
Next-generation sequencing (NGS), high-resolution molecular HLA typing, and advanced immunogenicity assessment platforms are the primary technologies driving growth in the US market.
Why is the US HLA typing market growing faster than the global average?
The US market grows at 6.5% CAGR compared to the global 6% due to higher transplant volumes, advanced healthcare infrastructure, strong reimbursement policies, and greater adoption of precision medicine technologies.
RESEARCH METHODOLOGY
This study analyzed market variables related to small and medium-sized businesses and major corporations to balance primary and secondary research for the human leukocyte antigen (HLA) typing for transplant market. The next phase involved conducting primary research with industry experts along the value chain to validate the findings, assumptions, and market sizing. Several methodologies were employed to estimate the overall market size, including both top-down and bottom-up approaches. This study focuses on key market segments, emerging trends, regulatory frameworks, and competitive environments. It also examines leading market players and their strategies within this sector. In conclusion, the total market size was determined using top-down and bottom-up approaches and data triangulation to arrive at the final figure. Ongoing primary research was conducted throughout the study to validate and test each hypothesis.
Secondary Research
During the study, secondary research utilized a variety of sources, including directories and databases such as Bloomberg Businessweek, D&B Hoovers, and Factiva. Additional materials included white papers, annual reports, SEC filings, and investor presentations. This research approach collects and generates data that offers comprehensive, technical, and market-focused insights into the HLA typing for transplant market. The data provides information on key players and market segmentation based on recent industry trends and significant market developments. Additionally, a database of leading industry figures was created through this secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the HLA typing for transplant market. The primary sources from the demand side include medical OEMs, CDMOs, and service providers. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*Others include distributors, suppliers, product managers, business development managers, marketing managers, and sales managers.
Note: Companies are categorized into tiers based on their total revenue. As of 2024, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the global HLA typing for transplant market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the HLA typing for transplants business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players/OEMs operating in the HLA typing for transplant market
- Mapping the annual revenue generated by major global players from the HLA typing segment (or the nearest reported business unit/product category)
- Revenue mapping of top players to cover at least ~75% of the global market share as of 2024
- Extrapolation of the revenue mapping of major players to derive the global value of the market
- Extrapolating the global value of the HLA typing for transplant market.
- Summation of market value for all segments and subsegments to achieve the actual value of the global HLA typing for transplant market
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global HLA typing for transplant market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, top-down and bottom-up approaches validated the HLA typing for transplant market.
Market Definition
HLA typing assays are critical in transplant immunology, as they facilitate the identification of HLA antigens essential for assessing donor-recipient compatibility and mitigating the risk of alloimmune rejection. These assays are pivotal in donor-recipient cross-matching, subject profiling, genotyping, and various diagnostic applications. Recent advancements in HLA typing technology, which enable high-resolution typing, afford precise delineation of HLA allele variations. This increased accuracy significantly enhances the predictive capability for transplant outcomes, thereby minimizing rejection and graft-versus-host disease incidence. As a result, these innovations are instrumental in making transplantation a more feasible and successful therapeutic option for patients.
Stakeholders
- Manufacturers of HLA typing products for transplant
- Distributors & suppliers of HLA typing products for transplant
- Hospitals, Transplant Centers, reference laboratories, Cord Blood Banks
- Research Laboratories and Academic Institutes
- Organ Procurement Organizations (OPOs)
- Non-government organizations
- Government regulatory authorities
- Contract manufacturers and third-party suppliers
- Clinical research organizations (CROs)
- Government and non-governmental regulatory authorities
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the HLA typing for transplant market based on product & service, technology, application, transplant type, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global HLA typing for transplant market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global HLA typing for transplant market
- To provide an average selling price trend for the target product categories in HLA typing for transplant market
- To analyze key growth opportunities in the global HLA typing for transplant market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), the Asia Pacific (Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
- To profile the key players in the global HLA typing for transplant market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global HLA typing for transplant market, such as product launches, agreements, expansions, and acquisitions
Get the Full HLA Typing for Transplant Market Report
Full forecast, segment splits, and company analysis for all HLA Typing for Transplant Market.
- Canada HLA Typing for Transplant Market
- Germany HLA Typing for Transplant Market
- UK HLA Typing for Transplant Market
- France HLA Typing for Transplant Market
- Spain HLA Typing for Transplant Market
- Italy HLA Typing for Transplant Market
- China HLA Typing for Transplant Market
- India HLA Typing for Transplant Market
- Japan HLA Typing for Transplant Market
- Australia HLA Typing for Transplant Market
- South Korea HLA Typing for Transplant Market
- Brazil HLA Typing for Transplant Market
- Mexico HLA Typing for Transplant Market
- Rest Of Europe HLA Typing for Transplant Market
- Rest Of Asia Pacific HLA Typing for Transplant Market
- Rest Of Latin America HLA Typing for Transplant Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
